acetyl-CoA + butirosin
acetylated at 30% the rate of gentamicin C1
487273
Providencia sp.
CoA + ?
?
acetyl-CoA + dideoxykanamycin
acetylated at 92% the rate of gentamicin C1
487273
Providencia sp.
CoA + N2'-diacetyldideoxykanamycin
?
acetyl-CoA + gentamicin B
7% of the activity with gentamicin C1
487273
Providencia sp.
CoA + N2'-acetylgentamycin
?
acetyl-CoA + gentamicin C1
best substrate
487273
Providencia sp.
CoA + N2'-acetylgentamicin C1
?
acetyl-CoA + gentamicin C1
best substrate
487273
Providencia sp. 164
CoA + N2'-acetylgentamicin C1
?
acetyl-CoA + gentamicin C1a
acetylated at 86% the rate of gentamicin C1
487273
Providencia sp.
CoA + N2'-acetylgentamicin C1a
?
acetyl-CoA + gentamicin C1a
acetylated at 86% the rate of gentamicin C1
487273
Providencia sp. 164
CoA + N2'-acetylgentamicin C1a
?
acetyl-CoA + kanamycin B
acetylated at 14% the rate of gentamicin C1
487273
Providencia sp.
CoA + N2-acetylkanamycin B
?
acetyl-CoA + kanamycin C
acetylated at 40% the rate of gentamicin C1
487273
Providencia sp.
CoA + N2'-acetylkanamycin C
?
acetyl-CoA + neomycin B
acetylated at 10% the rate of gentamicin C1
487273
Providencia sp.
CoA + N2'-acetylneomycin
?
acetyl-CoA + ribostamycin
acetylated at 15% the rate of gentamicin C1
487273
Providencia sp.
CoA + N2'-acetylribostamycin
?
acetyl-CoA + sisomicin
acetylated at 71% the rate of gentamicin C1
487273
Providencia sp.
CoA + N3'-acetylsisomicin
acetyl-CoA + sisomicin
acetylated at 71% the rate of gentamicin C1
487273
Providencia sp. 164
CoA + N3'-acetylsisomicin
acetyl-CoA + tobramycin
acetylated at 58% the rate of gentamicin C1
487273
Providencia sp.
CoA + N2'-acetyltobramycin
?
acetyl-CoA + tobramycin
acetylated at 58% the rate of gentamicin C1
487273
Providencia sp. 164
CoA + N2'-acetyltobramycin
?
acetyl-CoA of soluble fragments of peptidoglycan + tobramycin
acetylated at 58% the rate of gentamicin C1
487273
Providencia sp.
?
?
additional information
no substrates are kanamycin A and 1-hydroxyaminobutyric acid kanamycin A-derivative BB-K 8
487273
Providencia sp.
?
additional information
no substrates are kanamycin A and 1-hydroxyaminobutyric acid kanamycin A-derivative BB-K 8
487273
Providencia sp. 164
?
N-acetyl-D-glucosamine + tobramycin
acetylated at 58% the rate of gentamicin C1
487273
Providencia sp.
D-glucosamine + N2'-acetyltobramycin
?
acetyl-CoA + butirosin
acetylated at 30% the rate of gentamicin C1
487273
Providencia sp.
CoA + ?
?
acetyl-CoA + dideoxykanamycin
acetylated at 92% the rate of gentamicin C1
487273
Providencia sp.
CoA + N2'-diacetyldideoxykanamycin
?
acetyl-CoA + gentamicin B
7% of the activity with gentamicin C1
487273
Providencia sp.
CoA + N2'-acetylgentamycin
?
acetyl-CoA + gentamicin C1
best substrate
487273
Providencia sp.
CoA + N2'-acetylgentamicin C1
?
acetyl-CoA + gentamicin C1
best substrate
487273
Providencia sp. 164
CoA + N2'-acetylgentamicin C1
?
acetyl-CoA + gentamicin C1a
acetylated at 86% the rate of gentamicin C1
487273
Providencia sp.
CoA + N2'-acetylgentamicin C1a
?
acetyl-CoA + gentamicin C1a
acetylated at 86% the rate of gentamicin C1
487273
Providencia sp. 164
CoA + N2'-acetylgentamicin C1a
?
acetyl-CoA + kanamycin B
acetylated at 14% the rate of gentamicin C1
487273
Providencia sp.
CoA + N2-acetylkanamycin B
?
acetyl-CoA + kanamycin C
acetylated at 40% the rate of gentamicin C1
487273
Providencia sp.
CoA + N2'-acetylkanamycin C
?
acetyl-CoA + neomycin B
acetylated at 10% the rate of gentamicin C1
487273
Providencia sp.
CoA + N2'-acetylneomycin
?
acetyl-CoA + ribostamycin
acetylated at 15% the rate of gentamicin C1
487273
Providencia sp.
CoA + N2'-acetylribostamycin
?
acetyl-CoA + sisomicin
acetylated at 71% the rate of gentamicin C1
487273
Providencia sp.
CoA + N3'-acetylsisomicin
acetyl-CoA + sisomicin
acetylated at 71% the rate of gentamicin C1
487273
Providencia sp. 164
CoA + N3'-acetylsisomicin
acetyl-CoA + tobramycin
acetylated at 58% the rate of gentamicin C1
487273
Providencia sp.
CoA + N2'-acetyltobramycin
?
acetyl-CoA + tobramycin
acetylated at 58% the rate of gentamicin C1
487273
Providencia sp. 164
CoA + N2'-acetyltobramycin
?
acetyl-CoA of soluble fragments of peptidoglycan + tobramycin
acetylated at 58% the rate of gentamicin C1
487273
Providencia sp.
?
?
additional information
no substrates are kanamycin A and 1-hydroxyaminobutyric acid kanamycin A-derivative BB-K 8
487273
Providencia sp.
?
additional information
no substrates are kanamycin A and 1-hydroxyaminobutyric acid kanamycin A-derivative BB-K 8
487273
Providencia sp. 164
?
N-acetyl-D-glucosamine + tobramycin
acetylated at 58% the rate of gentamicin C1
487273
Providencia sp.
D-glucosamine + N2'-acetyltobramycin
?
487274
Payie
Characterization of gentamicin ...
Providencia stuartii
J. Bacteriol.
179
4106-4114
1997
-
-
-
-
-
-
-
-
-
-
-
1
-
2
-
-
1
-
-
-
-
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
1
-
-
-
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
487275
Clarke
The prevalence of gentamicin 2 ...
no activity in Morganella morganii, no activity in Proteus myxofaciens, no activity in Proteus vulgaris, no activity in Providencia heimbachae, no activity in Providencia rustigianii, Proteus penneri, Providencia rettgeri, Providencia stuartii, Providencia stuartii PR50
FEMS Microbiol. Lett.
145
201-207
1996
-
-
-
-
-
-
-
-
-
-
-
2
-
14
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
487276
Payie
The role of O-acetylation in t ...
Providencia stuartii
Microb. Drug Resist.
2
135-140
1996
-
-
-
-
-
-
-
-
-
-
-
1
-
5
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
487273
Chevereau
Aminoglycoside resistance in b ...
Providencia sp. 164, Providencia sp.
Biochemistry
13
598-603
1974
-
-
-
-
-
1
-
-
-
-
-
-
-
3
-
-
-
-
-
-
-
-
19
-
-
-
-
-
-
2
2
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
19
-
-
-
-
-
2
2
-
-
-
-
-
-
-
-
487272
Benveniste
Aminoglycoside antibiotic-inac ...
Streptomyces kanamyceticus, Streptomyces spectabilis
Proc. Natl. Acad. Sci. USA
70
2276-2280
1973
-
2
-
-
-
-
-
-
1
-
-
1
-
2
-
-
-
-
-
-
-
-
8
-
-
-
-
-
-
1
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
8
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-